Form 4: Summit Therapeutics COO and CFO, Manmeet Singh Soni, Reports Changes in Beneficial Ownership

Manmeet Singh Soni, COO and CFO of Summit Therapeutics Inc., reports an amendment to stock options, changing them from performance-based to time-based.

Summary

• On April 29, 2025, Manmeet Singh Soni, the COO and CFO of Summit Therapeutics Inc., reported changes in beneficial ownership to the SEC.
• The reported transaction involves an amendment to stock options.
• The stock options, initially performance-based, were converted to time-based options.
• The exercise price of the stock options is $1.68.
• A total of 11,200,000 stock options are involved in this transaction.
• 50% of the shares underlying the option vested on April 29, 2025.
• The remaining 50% will vest in three equal annual installments, starting on October 13, 2025.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing, so the sentiment is neutral.

Future Outlook

The remaining 50% of the shares will vest in three equal annual installments, with the first such installment occurring on October 13, 2025.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. The conversion of performance-based options to time-based options could be related to company performance or retention strategies.

Stakeholder Impact

• Shareholders may be interested in the vesting schedule of executive stock options.

Key Dates

Keywords

stock options, beneficial ownership, Form 4, Summit Therapeutics, Manmeet Singh Soni, COO, CFO